VIP (Vasoactive Intestinal Peptide): Research, Receptors, and Emerging Uses

Key takeaways

• VIP is a 28-amino-acid neuropeptide that acts through VPAC1 and VPAC2 receptors.
• Recent research shows VIP signaling can suppress T-cell activity, while VIP receptor antagonists can increase anti-leukemia responses in mouse models.
• VIP also has a role in glucose control, especially through VPAC2-linked, glucose-dependent insulin secretion.
• In the brain, VIP can increase firing in suprachiasmatic nucleus neurons and influence circadian timing.
• Across the literature, the main theme is the same: VIP is not a narrow signal. It affects immune, endocrine, and neural systems at once.

What VIP is

Vasoactive intestinal peptide, or VIP, is a 28-amino-acid neuropeptide. It is part of the glucagon/secretin family. Research describes it as a signal with broad effects across the body, not just one organ system. It works by binding two main receptors: VPAC1 and VPAC2.

Because these receptors are widely expressed, VIP can influence several kinds of cells. The sources in this set describe effects in immune cells, the pancreas, the hypothalamus, the lungs, and the enteric nervous system. That broad reach is why VIP keeps showing up in very different areas of research, from diabetes to leukemia.

Why receptor choice matters

VIP does not act in the same way everywhere. The receptor context matters. The Frontiers review notes that VIP can stimulate glucose-dependent insulin secretion, especially through VPAC2. Other studies in this bundle focus on VPAC1 in T cells, where VIP signaling reduces proliferation and inflammatory signaling. In other words, the same peptide can have different effects depending on which receptor is most active in a tissue.

VIP and the immune system

The strongest theme in the research bundle is immune regulation. VIP is described as anti-inflammatory in several sources. In the 2017 leukemia study, VIP signaling through VPAC1 on T cells led to reduced proliferation and lower pro-inflammatory cytokine secretion. Blocking that pathway with the peptide antagonist VIPhyb improved T-cell-dependent anti-leukemia responses in mouse models of acute myeloid leukemia and T lymphoblastic leukemia.

That same paper reports that subcutaneous VIPhyb reduced tumor burden and improved survival in treated mice. Survival in the treated group was 30% to 50%, compared with 0% to 20% in vehicle controls. The treated mice also had lower PD-1 levels on T cells and higher IFNγ secretion.

VIP receptor antagonism in newer leukemia work

A newer 2026 study went a step further. Researchers screened a combinatorial library of VIPhyb C-terminal variants to find stronger VIP receptor antagonists. They tested 15 peptides in mouse and human T cells and in a murine AML model. The study found that predicted receptor binding correlated positively with both mouse T-cell proliferation and anti-leukemia activity.

Two candidates stood out: ANT308 and ANT195. ANT308 showed high predicted VIP receptor binding, a low EC50 for in vitro T-cell activation, and strong anti-leukemia activity. The study also reported that ANT308 decreased CREB phosphorylation, which is a downstream VIP receptor signal, and increased granzyme B and perforin expression in CD8+ T cells from AML patients.

This does not mean VIP is simply “good” or “bad.” It means the pathway is biologically active, and changing it can alter immune behavior in measurable ways.

What the arthritis data suggest

The research bundle also includes a summary of earlier work in experimental arthritis. In that mouse model, VIP delayed disease onset, lowered incidence, and reduced severity of collagen-induced arthritis. The treated animals showed less inflammatory infiltrate, pannus formation, cartilage destruction, and bone erosion.

That report also describes reduced T-cell clonal expansion, lower inflammatory cytokines such as TNF and IL-1, higher anti-inflammatory cytokines such as IL-10 and IL-1 receptor antagonist, and reduced MMP-2 expression and activity. This fits the same basic pattern seen elsewhere: VIP signaling can shift immune activity away from inflammation.

VIP and glucose control

VIP is also relevant to metabolic research. A 2022 Frontiers review states that VIP can stimulate glucose-dependent insulin secretion, especially through VPAC2 receptors. That matters because glucose-dependent insulin release is the kind of effect researchers want in a hypoglycemia-sparing drug target.

The same review says VIP also promotes islet beta-cell proliferation through the forkhead box M1 pathway, although the exact molecular mechanism still needs more study. It also notes a practical problem: VIP has a short half-life and a wide distribution in the body, which limits direct clinical use.

Why VPAC2-selective agonists are being studied

Because of those limits, researchers have looked at VPAC2-selective agonists as a way to capture some of VIP’s glucose-related effects without relying on native VIP itself. The review frames this as a drug-development strategy for type 2 diabetes. The key point is narrow and specific: the literature in this set supports VIP as a signal linked to glucose-dependent insulin secretion, not as a finished diabetes treatment.

VIP and the brain clock

VIP also acts in the brain. In a study on the suprachiasmatic nucleus, VIP increased the spontaneous firing rate of dorsal SCN neurons during the night. The paper reports that 1 and 10 micromolar VIP produced a significant rise in firing rate, while 0.1 micromolar did not. The effect was not fleeting; it returned to control levels within 4 to 6 hours after VIP application.

That same study describes the effect as long-lasting and shows that VIP can alter neuronal activity in a way that outlives the immediate exposure window. This supports the idea that VIP is part of circadian control, not just a local gut peptide as older naming might suggest.

How to read the circadian finding

This result does not prove that VIP alone sets the body clock. It does show that VIP can change activity in a core circadian brain region. That makes it relevant to sleep-wake biology and to research questions about how neuropeptides shape timing signals in the nervous system.

What the newer antagonist work changes

The most important recent development in this bundle is the move from general VIP antagonism to more refined receptor-antagonist design. The 2026 paper is notable because it combined in silico modeling, T-cell assays, and animal leukemia work in one pipeline. The authors report that the predicted binding of VIP receptor antagonists to VIP receptors correlated positively with their ability to increase mouse T-cell proliferation and anti-leukemia activity.

That finding matters because it ties together computational predictions and biology in the same direction. ANT308 and ANT195 emerged as top candidates for further development. The study presents them as promising immunotherapy leads for relapsed AML, not as ready-made treatments.

What this means for research use

For researchers, VIP is now interesting in two opposite ways. One path studies VIP or VIP-like agonism to preserve signaling in systems where anti-inflammatory or glucose-dependent effects may matter. The other path studies antagonists to release T cells from VIP-driven suppression in cancer models. The pathway can be approached from both sides because it sits at a control point.

Practical reading of the evidence

The research set does not support a simple one-line story. VIP is a regulatory peptide with effects in several systems. In immune work, it tends to push toward less inflammation and less T-cell activity. In diabetes-related work, it can support glucose-dependent insulin secretion through VPAC2. In circadian work, it changes firing in SCN neurons. In leukemia models, blocking the pathway can help T cells attack cancer.

That range is the main takeaway. VIP is not a single-purpose molecule. It is a signaling hub with context-specific effects. In some settings, researchers want more of that signal. In others, they want less.

The literature here also makes one practical limitation clear: native VIP has short half-life and broad distribution, which is one reason the field keeps turning toward receptor-selective analogs and antagonists rather than the unmodified peptide alone.

FAQ

What is VIP in simple terms?

VIP is a 28-amino-acid neuropeptide. It sends signals through VPAC1 and VPAC2 receptors and affects immune, brain, and metabolic function.

Does VIP reduce inflammation?

Yes, several studies in this bundle describe VIP as anti-inflammatory. In T cells, VIP signaling reduced proliferation and lowered pro-inflammatory cytokine secretion. In arthritis models, VIP was linked to lower inflammatory activity and less tissue damage.

Why are VIP receptor antagonists being studied in leukemia?

Because VIP signaling can suppress T-cell activity. In mouse AML and T-cell leukemia models, blocking the pathway with antagonists such as VIPhyb improved anti-leukemia responses. A newer study found stronger candidates, including ANT308 and ANT195.

What is the evidence for VIP in diabetes research?

A 2022 review reports that VIP can stimulate glucose-dependent insulin secretion, especially through VPAC2 receptors, and may promote beta-cell proliferation. The same review says clinical use is limited by VIP’s short half-life and broad tissue distribution.

Does VIP affect sleep or circadian rhythm?

Yes. In a study of the suprachiasmatic nucleus, VIP increased neuronal firing during the night, and the effect lasted several hours after exposure. That supports a role for VIP in circadian timing.

Is VIP a treatment for any condition yet?

Not based on the sources here. The research supports VIP as a biologically important target and a tool for drug development, but the studies described are still in preclinical or review stages.